ArticleEuropean journal of medical research2026
Integrated transcriptomic analysis and experimental validation identify ACADL as a mitochondrial tumor suppressor via the FOXO3a/PUMA axis in lung adenocarcinoma.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial dysfunction represents a recognized hallmark of cancer; however, the underlying molecular mechanisms contributing to this process in lung adenocarcinoma (LUAD) remain incompletely understood.
methodsDifferentially expressed genes (DEGs) in LUAD were identified by integrating datasets (GSE7670, GSE10072, and GSE32863), and were subsequently cross-referenced with mitochondria-related genes from the MitoCarta3.0 database. Hub genes were identified using the least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE) algorithms. LUAD cell lines and xenograft models with stable overexpression of acyl-CoA dehydrogenase long chain (ACADL) were subsequently established. To assess the involvement of the FOXO3a/PUMA signaling axis in mediating tumor suppression, the selective FOXO3a inhibitor AS1842856 was employed.
resultsEight hub genes (ACADL, BIK, CAT, COX7A1, PAICS, PDK4, PRDX4, and PYCR1) demonstrated high diagnostic accuracy for LUAD, with area under the curve (AUC) values exceeding 0.80. ACADL, CAT, PDK4, and COX7A1 were significantly downregulated, whereas BIK, PAICS, PYCR1, and PRDX4 were upregulated in A549 and H1299 LUAD cell lines. Functional assays revealed that overexpression of ACADL suppressed cell proliferation, migration, and invasion, while inducing apoptosis in LUAD cells. Mechanistically, ACADL impaired mitochondrial bioenergetics by reducing intracellular ATP levels and promoting reactive oxygen species (ROS) accumulation. Additionally, ACADL enhanced mitochondrial fission by upregulating Drp1 and Fis1, and downregulating Mfn2 expression. Further mechanistic investigations indicated that ACADL activated the FOXO3a/PUMA signaling axis. In vivo, ACADL expression markedly inhibited tumor growth and disrupted mitochondrial homeostasis, an effect that was significantly attenuated upon administration of the FOXO3a inhibitor AS1842856.
conclusionACADL functions as a mitochondria-associated tumor suppressor that impedes LUAD progression through activation of the FOXO3a/PUMA signaling pathway, underscoring its potential as a therapeutic target for LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.